Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to 48.59%.

  • United Therapeutics' EBIT Margin rose 27800.0% to 48.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.63%, marking a year-over-year increase of 29200.0%. This contributed to the annual value of 47.86% for FY2024, which is 30500.0% down from last year.
  • Per United Therapeutics' latest filing, its EBIT Margin stood at 48.59% for Q3 2025, which was up 27800.0% from 45.64% recorded in Q2 2025.
  • United Therapeutics' 5-year EBIT Margin high stood at 26010.0% for Q4 2023, and its period low was 4527.85% during Q4 2024.
  • Moreover, its 5-year median value for EBIT Margin was 48.59% (2025), whereas its average is 1171.43%.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 259742700bps in 2023, then tumbled by -305378500bps in 2024.
  • Over the past 5 years, United Therapeutics' EBIT Margin (Quarter) stood at 40.9% in 2021, then decreased by -13bps to 35.73% in 2022, then soared by 72701bps to 26010.0% in 2023, then tumbled by -117bps to 4527.85% in 2024, then surged by 101bps to 48.59% in 2025.
  • Its last three reported values are 48.59% in Q3 2025, 45.64% for Q2 2025, and 48.19% during Q1 2025.